Biotech Industry Fears Fallout From Supreme Court’s Myriad Ruling; PTO Offers Guidance
Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can; Patent and Trademark Office tells examiners to reject product claims drawn solely to naturally occurring nucleic acids or their fragments.
You may also be interested in...
BIO, PhRMA, AAM, former PTO Commissioners to testify at two-day Senate hearing on draft bill to revise Section 101 of Patent Act; ACLU coalition says legislation will allow patenting of human genes.
Yielding to industry pressure, Patent and Trademark Office says both structural and functional changes to what exists in nature should to be considered in assessing patent claims.
The outcome of ACLU’s suit challenging Myriad Genetics’ BRCA cancer genes is crucial for the biotech industry as it could prevent companies from getting patents on therapeutics that utilize DNA and other isolated molecules.